Method for producing polypeptide

Abstract: The present invention provides a method for producing a polypeptide, which comprises condensing precursors comprising an amino acid and an adaptor in the presence of ribosomes, rRNAs, a larger ribosomal subunit or ribosomal proteins, and an aromatic tertiary amine.

Description: The present invention relates to a method for producing polypeptides. As a method for producing polypeptide in the cell-free translation system, there has been known a method which required ribosomes, chemical energy sources such as ATP and GTP, and soluble protein factors. However, the method was not always satisfactory in that the method required energy sources and soluble protein factors. Therefore, the conventional method was so complicated that it was not practical for producing polypeptide. Other methods for producing polypeptides are described in US Patent No. 4,440,676 disclosing a process for the production of a dipeptide, a polypeptide or a protein whereby an end amino group and an end carboxyl group are directly combined using pentaco-ordinate spirophosphorane as a coupling agent to form a peptide linkage. WO 88/08453 discloses a cell-free translation system on ribosomes containing as substrates ATP, GTP and amino acids. As the substrates are consumed and the products being the translation products as well as AMP, GDP, pyrophosphate and inorganic phosphate are obtained the products are extracted while the substrates are simultaneously introduced into the system. Under the circumstances, the present inventors have intensively studied the method for producing polypeptides in the cell-free translation system, and have found that the condensation of a precursor comprising amino acids and adaptors can be effectively performed in the absence of the energy source such as ATP and GTP, and soluble protein factors but in the presence of rRNAs and an aromatic tertiary amine other than GTP or ATP. Thus, the present invention provides a method for producing a polypeptide, which comprises condensing precursors comprising an amino acid and an adaptor in the absence of soluble protein factors, GTP and ATP in the presence of rRNAs, and an aromatic tertiary amine other than GTP or ATP. It also provides a method for producing a polypeptide, which comprises the steps of; (a) reacting an amino acid with an adaptor molecule in the presence of aminoacyl-tRNA synthetase to obtain a precursor comprising an amino acid and a nucleic acid adaptor; and (b) condensing the precursors in the absence of soluble protein factors, GTP and ATP in the presence of rRNAs, and in the presence of an aromatic tertiary amine other than GTP or ATP. According to the present invention, the condensation of precursors comprising an amino acid and an adaptor can be effectively carried out without energy source such as ATP and GTP and soluble protein factors but in the presence of rRNAs and an aromatic tertiary amine other than GTP or ATP. First, description will be made on the method for producing a polypeptide, which comprises condensing precursors comprising an amino acid and an adaptor in the absence of soluble protein factors, GTP and ATP in the presence of rRNAs, and in the presence of an aromatic tertiary amine other than GTP or ATP. The condensation reaction of the precursors is usually carried out in the absence of soluble protein factors, GTP and ATP in the presence of rRNAs, and in the presence of an aromatic tertiary amine other than GTP or ATP. Ribosomes, the rRNA or the larger ribosomal subunit are obtained by a conventional method such as extraction from cell organs or organisms which can be obtained from nature or purchased. The ribosomes of the E. coli are obtained by the following procedures. For example, E, coli cells are mixed with a buffer solution and crushed with a mortar or pressed by the French press to give a suspension, which is then subjected to ultracentrifugation to give a supernatant. Then the supernatant is separated by centrifugation to give the ribosomes of E. coli. Furthermore, the larger ribosomal subunit can be obtained by the known sucrose density gradient method. The organisms which may be eucaryote or procaryote include, for example, mammals, insects, plants such as algae, mosses, fern, gymnosperm, angiosperm, fungi, bacteria, molds and yeasts. Preferable examples of the organisms are: mammals including rat, mouse, cow and goat; algae including green algae and blue-green algae; angiosperm including wheat, rice, tobacco, tomato and the like; bacteria including Escherichia , Bacillus , Pseudomonas and the like; molds including Neurospora , Aspergillus , Penicillium and the like; and yeasts including Saccharomyces and the like. Thermophilic bacteria such as Bacillus strearothermophilus , aquiatucus and Thermus thermophilus which are not only resistant to high temperature but also less sensitive to denaturation by an organic solvent are preferably used as the source of the ribosomes, the rRNA or the larger ribosomal subunit. As the cell organs mitochondria and chloroplasts may be exemplified. The ribosomes washed with an aqueous cation solution of high concentration may be used in the present invention. The extraction of the ribosomal protein is carried out by conventional methods such as described in "Ribosomes and Protein Synthesis A practical Approach (G. Spedding, Oxford University Press, 1990)". The aromatic tertiary amine compounds to be used in the present process include pyridine compounds, imidazole compounds, purine base compounds and pyrimidine base compounds. The pyridine compounds to be used in the present method can be represented by the formula I: wherein R independently represents a member selected from the group of a hydrogen atom, a halogen atom, a C 1 -C 4 aliphatic hydrocarbon group, an amino group, a C 5 -C 8 alicyclic hydrocarbon group, a C 6 -C 10 aromatic hydrocarbon group, a hydroxyl group, a sulfhydryl group and a heterocyclic group having at least one heteroatom, all of which except the hydrogen atom and the halogen atom may be optionally substituted; alternatively R represents a group of the formula: -COQ, wherein Q represents a hydrogen atom, a C 1 -C 4 aliphatic hydrocarbon group, an amino group, a C 5 -C 8 alicyclic hydrocarbon group, a C 6 -C 10 aromatic hydrocarbon group, a hydroxyl group a sulfhydryl group or a heterocyclic group having at least one heteroatom, all the groups of which may be optionally substituted; and p represents an integer of 1 to 5. The imidazole compounds to be used in the present method may be represented by the formula II: wherein R is the same as defined above; R' represents the same atoms or groups as those given in R provided that it excludes a halogen atom, an amino group, a hydroxyl group and a sulfhydryl group, and those atoms and groups are also excluded in Q; R and R' are independent from each other; and m represents an integer of 1 to 3. The purine base compounds include a compound represented by the formula III: wherein R and R' are the same as defined above and independent from each other; and m represents an integer of 1 to 3, and a compound of the formula IV: wherein R and R' are the same as defined above, R" represents the same atoms or groups with those given in R provided that it excludes a halogen atom, an amino group, a hydroxyl group and a sulfhydryl group, and those atom and groups are also excluded in Q; R, R' and R" are independent from each other; and k represents an integer of 1 or 2. The pyrimidine base compounds include a compound represented by the formula V: wherein R is the same as defined above and n represents an integer of 1 to 4; a compound of the formula VI: wherein R, R' and n are the same as defined above and R and R' are independent from each other; and a compound of the formula VII: wherein R and R' are the same as defined above and independent from each other, and m represents an integer of 1 to 3. In the chemical formulae I to VII above, examples of the C 1 -C 4 aliphatic hydrocarbon group for R, R' and R" are a methyl group, an ethyl group, a n-propyl group, an isopropyl group, a n-butyl group, a sec.-butyl group, an isobutyl group and a tert.-butyl group. Examples of the C 5 -C 8 alicyclic hydrocarbon group are a cyclopentyl group, a cyclohexyl group, a cyclohepty group and a cyclooctyl group. Examples of the C 6 -C 10 aromatic hydrocarbon group are a phenyl group and a naphthyl group. Examples of the halogen atom are a fluorine atom, a chlorine atom, a bromine atom and an iodine atom. Examples of the heteroatom in the heterocyclic group are an oxygen atom, a nitrogen atom or a sulfur atom. Examples of the heterocyclic group having at least one heteroatom which group may be optionally substituted are a ribosyl group, a deoxyribosyl group and monophosphate, phosphodiester and triphosphate derivative thereof. Examples of the pyridine compound are α-picoline, β-picoline, γ-picoline, 2-aminopyridine, 3-aminopyridine, 4-aminopyridine and 4-dimethylaminopyridine. Examples of the imidazole compound are imidazole and 1-methylimidazole. Examples of the purine base compound are guanine, adenine, 9-methyladenine, 7-methyladenine, adenosine, 2'-deoxyadenosine, adenosine 5'-monophosphate and adenosine 5'-diphosphate Examples of the pyrimidine base compound are cytosine, uracil, thymine, cytidine, 2'-deoxycytidine, cytidyl 5'-monophosphate and cytidyl 5'-diphosphate. However, the aromatic tertiary amines are not limited thereto. The concentration of the aromatic tertiary amine is not specified and the preferable concentration of the aromatic tertiary amine varies according to the kinds of the base. However, the preferable concentration of the aromatic tertiary amine is usually within the range of from the saturation concentration to water to 1/10 9 or preferably 1/10 6 of the saturation concentration. For example, the preferable concentration for pyridine, pyrimidine or imidazole is 10nM to about 10M; 1nM to about 1M for purine, 2-aminopyridine, 4-aminopyridine or 4-dimethylaminopyridine; 100pM to about 100mM for adenosine 5'-diphosphate or cytidyl 5'-diphosphate; and 10pM to about 10mM for adenine or guanine. The pH of the condensation reaction solvent is not specified, however, preferably 5 to 11, more preferably 6 to 10 in terms of the yield. The present condensation reaction is preferably carried out in the presence of appropriate cations such as a magnesium ion and at least one ion selected from a potassium ion and an ammonium ion to proceed the condensation reaction more efficiently. The concentration of the potassium ion or ammonium ion is preferably 50mM to 500nM, more preferably 100mM to 300mM. As for the concentration of the magnesium ion, it is preferably 1mM to 500mM, more preferably 5mM to 300mM. A metal ion such as a zinc ion, an iron ion, a copper ion or a manganese ion may be added to accelerate the condensation reaction. The reaction temperature is usually 0 to 90°C. When the ribosomes of a highly thermophilous bacteria are used, the reaction can be carried out at the range of 30 to 90°C. When the ribosomes of a thermophilic bacteria are used, the reaction temperature is preferably 30 to 80°C. When other ribosomes are used, the reaction temperature is preferably 30 to 70°C, more preferably 30 to 60°C. The present condensation reaction may be conducted in the presence of other additives to accelerate the condensation reaction. Examples of such additives include polyamines such as spermine and spermidine, polyethylene glycols, glyrerols and alcohols. The present reaction is preferably conducted in the presence of a template molecule comprising a nucleic acid which interacts with the adaptor molecules. Examples of such a template molecule include an mRNA of interest or the derivatives thereof that is present in living cells or an mRNA obtained by synthetic or enzymatic methods. Furthermore, a compound such as polyuridylic acid (poly(U)), polyadenylic acid (poly(A)) or a block copolymer thereof (e.g., poly(UA)) that represents the synthetic functions of the mRNA may also be used as the template. A nucleic acid coding for a useful protein may be also used as the template. Examples of the useful proteins are a biologically active peptide such as human growth hormones, protein pharmaceuticals, proteins involved in antigen-antibody reaction and enzymes that catalyze the biological processes. The precursors comprising amino acids and adaptors includes an aminoacyl-tRNA, which is usually obtained by reacting an amino acid with the tRNA molecule as the adaptor in the presence of aminoacyl-tRNA synthetase or may be chemically synthesized from an amino acid and a corresponding adaptor. The amino acids to be used in the present invention may be a compound having a carboxylic acid group and an amino group in the same molecule and may also be a naturally occurring or non-naturally occurring type. The carbon atom to which the amino group is bonded may be at any position of the carbon chain to which the carboxylic acid group is bonded, and the number of the amino group and the carboxylic acid group present in the molecule is not limited. When the said amino acids possess a chiral center, they include an L-amino acid, a D-amino acid and a racemic mixture thereof. Examples of the amino acid to be used in the present method are: protein constituent (naturally occurring) amino acids such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and derivatives thereof; β-alanine, γ-aminobutyric acid, 5-aminolevulinic acid and derivatives thereof, all of which are present in living cells; and amino acids that do not exist in the living cells such as p-, m- or o-aminobeozoic acid. Examples of adaptors include nucleic acids such as tRNAs (for example, those described in G.Fasman, ed, "Handbook of Biochemistry and Molecular Biology" 3rd Ed., Vol 2, p. 423 CRR press (1975), and D.H. Gauss, M.Sprizl, Nucleic Acids Res, 9, r1 (1981)) or a variant thereof that can be specifically combined to the corresponding amino acids which are present in living cells or obtainable by an enzymatic or synthetic methods. The reaction of the adaptor with the amino acid is, for example, carried out in the presence of the aminoacyl-tRNA synthetase, which can be obtained by such a method as described in "Seikagaku Jikken Koza", vol. 7, Chapter 1, Edited by Biochemical society of Japan, 1975. The reaction may be also conducted by a synthetic method. The reaction of the adaptors with the amino acids may be, for example, carried out in a single reaction vessel or in separate reaction vessels for each of the amino acids at about 37°C. Then the solution is supplied for the subsequent condensation reaction while the concentrations of the reactants are adjusted to specified concentrations, if necessary. After the precursor such as an aminoacyl-tRNA is obtained, it can be recovered from the reaction mixture and then supplied to the condensation reaction. After completion of the reaction, the polypeptide can be obtained by a conventional post-treatment. Next, the present invention will be explained in detail by the following examples, however, it is not construed to limit the present invention thereto. Example 1 A solution of 5mM MgCl 2 , 10mM KCI, 2mM ATP, 5 µCi/ml (L)-[ 14 C]Phenylalanine and 3.0 A 280 /ml aminoacyl-tRNA synthetase (the designation expresses the concentration of the aminoacyl-tRNA synthetase with an absorbance value at 280nm for 1ml of the solution ), which was obtained from the cell extract solution of E. coli A19, in 200 µl was prepared. The extraction of the enzyme was carried out according to the method described in "Seikagaku Jikken Koza", vol. 7, Chapter 1, Edited by Biochemical society of Japan, 1975. The resultant reaction mixture was allowed to react at 37°C for 5 min to obtain a phenylalanyl-tRNA (which will be referred to as "[ 14 C]Phenylalanyl-tRNA or Phe-tRNA Phe " hereinafter) as the precursor for condensation. Then the [ 14 C]Phenylalanyl-tRNA was recovered after phenol extraction using a centrifugal concentration (Microcon-10, Amicon; 12,000rpm, at 0°C, for 1 hr, three times). The final stock buffer contained 37.5 µg/ml(1,500cpm/µl) Phe-tRNA Phe , 20mM NaOAc (pH 4.5) and 5mM MgCl 2 . Next, a solution of 15mM MgCl 2 , 120mM KCI and 16 A 260 /ml ribosomes derived from E. coli A19 in 25 µl was prepared using 1 µl of the Phe-tRNA Phe solution obtained above (two replicate). The preparation method was in accordance with that described in 'Ribosomes and Protein Synthesis A Practical Approach" (G.Spedding, Oxford University Press, 1990). One of the solutions prepared above was made an aqueous 50 % pyridine solution, and then allowed to react at 37°C for 60 min to give polyphenylalanine, Then 10 µl of water and 1 µl of 1N potassium hydroxide were added to the reaction solution and the reaction mixture was allowed to react at 37°C for 60 min to hydrolyze the unreacted Phe-tRNA Phe . The aliquots of the obtained reaction solution were subjected to the thin layer chromatography on a silica-plate(Silica - Gel 60, Merck) using a solvent system of 1-butanol/water/acetic acid=4/1/1 and visualized by an imaging analyzer (BAS 2000 made by Fuji Photo Film Co., Ltd.) After 12 hours, the [ 14 C]polyphenylalanine was identified by the Rf value of exceeding 0.58, which corresponds to that of an authentic trimer sample. It has been found that the obtained polyphenylalanine is a polypeptide composed of more than ten amino acids by the HPLC(high performance liquid chromatography) analysis. When the ribosomes were absent in the present reaction system, the condensation reaction did not take place. Example 2 The reaction was carried out in a similar manner to that in the Example 1 but using Thermus thermophilus , HB 27 in place of the E. coli , and yielded polyphenylalanine. Example 3 The reaction was carried out in a similar manner to that in the Example 1 but using Thermus thermophilus , HB 27 in place of the E. coli at 60°C, and yielded polyphenylalanine. Example 4 Ribosomes obtained from the E. coli was subjected to centrifugation using 10 %-20 % sucrose density gradient to separate the larger subunit and the smaller subunit. Among the obtained subunits, only the larger subunit could effectively produce polyphenylalanine as in the Example 1. Example 5 Ribosomes obtained from the E. coli was contacted with phenols to remove the protein to yield the ribosomal RNA and the condensation reaction was carried out in the presence of the ribosomal RNA and in a similar manner to that in the Example 1, and yielded polyphenylalanine. Example 6 Ribosomes were digested by 1mg/ml of the proteinase K in the presence of 0.5% sodium dodecyl sulfate at 37°C for 1 hour to remove the ribosomal protein. The condensation reaction was carried out in the presence of the rRNA in place of the ribosomes and in a similar manner to that in the Example 1, and yielded polyphenylalanine. Example 7 In this example, 0.4 mg/ml polyuridylic acid made by Sigma Corp, was used as the template while other reaction conditions were the same as in the Example 1. After completion of the reaction, the aliquots of the obtained reaction solution were subjected to the thin layer chromatography on a silica-plate(Silica-Gel 60, Merck) using a solvent system of 1-butanol/water/acetic acid=4/1/1 and visualized by an imaging analyzer (BAS 2000 made by Fuji Photo Film Co., Ltd.) After 12 hours, the [ 14 C]polyphenylalanine was identified by the Rf value of exceeding 0.58 When the ribosomes or the pyridine was absent in the present reaction system, the condensation reaction did not take place. Example 8 ∼ 19 In these examples the condensation reactions were carried out in a similar manner to that in the Example 7 except that the concentrations of the magnesium ion and the potassium ion were varied as shown in the following Table 1. The yield of polyphenylalanine was calculated based on the intensity of the radioactivity. Example No. Magnesium ion (mM) Potassium ion (mM) Yield (%) 8 0.6 120 73.2 9 5.6 120 75.6 10 10.6 120 70.3 11 15.6 120 66.7 12 20.6 120 68.6 13 50.6 120 65.1 14 100.6 120 51.1 15 15.6 52 9.9 16 15.6 122 66.7 17 15.6 242 75.0 18 15.6 502 73.8 19 15.6 802 62.3 Example 20 ∼ 26 In these examples the condensation reactions were carried out as- in the Example 7 except that the reaction temperature was varied as shown in the following Table 2. The yield of the polyphenylalanine was calculated based on the intensity of the radioactivity. Example No. Temperature(°C) Yield (%) 21 0 22.6 22 15 24.6 23 30 68.9 24 37 69.3 25 50 74.2 26 60 71.2 27 80 31.7 Example 27 ∼ 33 In these examples the condensation reactions were carried out in a similar manner to that in the Example 7 except that the concentration of the pyridine was varied as shown in the following Table 3. The yield of the polyphenylalanine was calculated based on the intensity of the radioactivity. Example No. Concentration of pyridine (V%) Yield (%) 27 70 10.0 28 65 25.8 29 60 33.9 30 55 60.2 31 50 69.5 32 40 45.0 33 30 9.5 Control 0 2.0 Example 34 In this example the condensation reaction was carried out in a similar manner to that in the Example 7 except that an aromatic tertiary amine such as N,N-dimethylaniline, 4-dimethylaminopyridine, adenine, adenosine, adenosinetriphosphate, guanine, guanosine and /or guanosinetriphosphate were used in place of the pyridine, and yielded polyphenylalanine. Example 35 In this example the condensation reaction was carried out in a similar manner to that In the Example 7 except that a ribosomal RNA obtained by removing proteins from the whole ribosome using phenol or the like was used in place of the whole ribosomes derived from the E. coli , and yielded polyphenylalanine. Example 36 Using phenylalanine and lysine, block copolymeric ribonucleic acid represented by the formula: as the template and the whole ribosome, a subunit thereof or rRNA, which are obtained from E. coli or thermophilous bacterium, the condensation reactions are carried out in a similar manner to that in the Example 7. An alternate copolymer with highly regulated coordination comprising the repeating unit structure: -(-Phe-Lys-)- was produced. Example 37 ∼ 48 In these examples the reactions were carried out in a similar manner to that in the Example 7 except that the concentrations of the magnesium and potassium ions were adjusted to 200mM, the reaction time was adjusted to 12 hours, and the concentrations of the aromatic tertiary amine were adjusted to the specified concentrations listed in the following Table 4. Table 4 shows the results of the experiments where the pyridines, imidazoles, purine bases and pyrimidines were used and it also provides the yield of polyphenylalanine. Example Concentration(mM) (100.0 50.0 10.0 5.0 1.0 0.2) YIELD(%) 37 4-Dimethylaminopyridine 13.7 14.1 17.1 16.9 38 4-Aminopyridine 13.7 13.0 17.6 17.6 39 2-Aminopyridine 24.6 20.4 17.0 15.9 40 Imidazole 13.8 12.3 8.8 9.4 41 1-Methylimidazole 8.8 8.8 7.7 6.9 42 Purine 26.3 26.3 21.2 18.2 43 Adenine 19.9 16.8 10.7 44 Adenosine 19.8 18.4 18.6 6.6 45 2'-Deoxyadenosine 18.4 18.0 15.7 8.8 46 Adenosine 5'-phosphate 12.6 12.5 11.9 9.6 47 Pyrimidine 17.5 17.6 18.1 18.1 48 Cytosine 15.3 14.2 11.7 10.6 Example 49 Ribosomes were digested by 1mg/ml of the proteinase K in the presence of 0.5 % sodium dodecyl sulfate at 37°C for 1 hour to remove the ribosomal protein. Thus obtained rRNA was used in place of the ribosomes to produce polyphenylalanine in a similar manner to that in the Example 7, which yielded polyphenylalanine.. Example 50 In this example a highly thermophilic bacterial ( Thermus thermophilus , HB 27) was used in place of the E. coli in the Example 7, which yielded polyphenylalanine. Example 51 Polylysine was produced from lysine using ribosomes of E. coli as in the Example 7 or using ribosomes of thermophilic bacterial (Thermus thermophilus , HB 27) as in the Example 50 and the polyadenilyic acid as the template. Example 52 The dihydrofolic acid reductase was produced from the twenty natural amino acids using an RNA coding for the dihydrofolic acid reductase as the template while other reaction conditions were the same as employed in the Example 7. Example 53 The ribosomes obtained from the E. coli were subjected to centrifugation using 10 %-20 % sucrose density gradient to separate the larger subunit and the smaller subunit. Among the obtained subunits, the larger subunit was effective for producing polyphenylalanine when used in place of the ribosomes used in the Example 7.

Claims: A method for producing a polypeptide, which comprises condensing precursors comprising an amino acid and a nucleic acid adaptor in the absence of soluble protein factors and bath GTP and ATP, but in the presence of rRNAs and an aromatic tertiary amine other than GTP or ATP. A method for producing a polypeptide, which comprises the steps of; (a) reacting an amino acid with a nucleic acid adaptor molecule in the presence of aminoacyl-tRNA synthetase to obtain a precursor comprising an amino acid and a nucleic acid adaptor; and (b) condensing the precursors in the absence of soluble protein factors and both GTP and ATP, but in the presence of rRNAs and an aromatic tertiary amine other than GTP or ATP. A method for producing a polypeptide according to Claim 1 or 2, wherein the condensation of the precursors is carried out in the presence of a template molecule consisting of a nucleic acid interacting with the adaptor molecule. A method for producing a polypeptide according to Claim 3, wherein the aromatic tertiary amine compound is a member selected from a group consisting of (a) a pyridine compound of the formula I: wherein R independently represents a member selected from a group of a hydrogen atom, a halogen atom, a C 1 -C 4 aliphatic hydrocarbon group, an amino group, a C 5 -C 8 alicyclic hycrocarbon group, a C 6 -C 10 aromatic hydrocarbon group, a hydroxyl group, a sulfhydryl group or a heterocyclic group having at least one hetero atom, all of which except the hydrogen atom and the halogen atom may be optionally substituted; alternatively R represents a group of a formula: -COQ, wherein Q represents a hydrogen atom, a C 1 -C 4 aliphatic hydrocarbon group, an amino group, a C 5 -C 8 alicyclic hydrocarbon group, a C 6 -C 10 aromatic hydrocarbon group, a hydroxyl group, a sulfhydryl group or a heterocyclic group having at least one heteroatom, all the groups of which may be optionally substituted; and p represents an integer of 1 to 5; (b) an imidazole compound of the formula II: wherein R is the same as defined above; R' represents the same atoms or groups with those given in R provided that it excludes a halogen atom, an amino group, a hydroxyl group and a sulfhydryl group, and those atoms and groups are also excluded in Q; R and R' are independent from each other; and m represents an integer of 1 to 3; (c) a purine base compound represented by the formula III: wherein R and R' are the same as defined above and independent from each other, and m represents an integer of 1 to 3, or the formula IV: wherein R and R' are the same as defined above; R" represents the same atoms or groups with those given in R provided that it excludes a halogen atom, an amino group, a hydroxyl group and a sulfhydryl group, and those atom and groups are also excluded in Q; R, R' and R" are independent from each other; and k represents an integer of 1 or 2; and (d) a pyrimidine base compound represented by the formula V: wherein R is the same as defined above and n represents an integer of 1 to 4, the formula VI: wherein R, R' and n are the same as defined above and R and R' are independent from each other; or the formula VII: wherein R and R' are the same as defined above and independent from each other; and m represents an integer of 1 to 3 A method for producing polypeptides according to Claim 4, wherein R represents a hydrogen atom, a methyl group, an amino group or a dimethylamino group, and R' and R" represent independently a hydrogen atom, a methyl group, a ribosyl group, a deoxyribosyl group, a 5'-monophosphoribosyl group, a 5'-monophosphodeoxyribosyl group, 5'-diphosphoribosyl group or a 5'-diphosphodeoxyribosyl group. A method for producing polypeptides according to Claim 4, wherein the pyridine compound is α-picoline, β-picoline, γ-picoline, 2-aminopyridine, 3-aminopyridine, 4-aminopyridine or 4-dimethylaminopyridine; the imidazole compound is imidazole or 1-methylimidazole; the purine compound is guanine, adenine, 9-methyladenine, 7-methyladenine, adenosine, 2'-deoxyadenosine, adenosine 5'-monophosphate or adenosine 5'-diphosphate; and the pyrimidine compound is cytosine, uracil, thymine, cytidine, 2'-deoxycytidine, cytidyl 5'-monophosphate, cytidyl 5'-diphosphate.

Inventors: NITTA ITARU, UEDA TAKUYA, WATANABE KIMITSUNA, NITTA, ITARU, UEDA, TAKUYA, WATANABE, KIMITSUNA
Applicants: SUMITOMO CHEMICAL CO, SUMITOMO CHEMICAL COMPANY, LIMITED
Application year: 1994
Main classification: C12P21
IPC codes: C12P21